Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Epidermolysis Bullosa Clinical Trial

Official title:

Survey to Identify Burdens and Unmet Needs of EB Patients in the US

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03158662
• Other study ID #: EB Survery 2017
• Status: Completed
• Phase: N/A
• First received: May 10, 2017
• Last updated: August 23, 2017
• Start date: April 2, 2017
• Est. completion date: June 30, 2017

Study information

• Verified date: August 2017
• Source: Amicus Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This survey intends to collect information on key aspects of life with epidermolysis bullosa (EB), including diagnostic journey, treatment, management, daily living challenges, and overall psycho-social, socio-economic, academic and family impact.

Objectives:

• To understand the unmet needs for people living with EB in the US

• To assess the differences/similarities in the management/treatment of EB patients (including wound care, symptom management and other issues)

• To assess the EB patients' and caregivers' perceptions of current management/treatment

• To assess the challenges and the burden of daily living with EB

• To understand EB diagnostic journey (the time to diagnosis and by what type of healthcare provider)

• To identify professional disciplines involved in the diagnosis and management of EB

• To understand the psycho-social, socio-economic, academic, and family impact of EB

Description:

Epidermolysis bullosa (EB) is a rare, often severe genetic disorder characterized by mechanical fragility and blistering or erosion of the skin, mucosa, or epithelial lining of other organs, in response to little or no apparent trauma.

EB is chronic, potentially disfiguring, and in some cases fatal. Patients with EB have painful wounds and blisters that can lead to infection and scarring. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. There is currently no approved treatment for EB. Current standard of care consists of pain management and the bandaging and cleaning of open wounds to prevent infection.

While there are a number of publications/guidance/consensus statements related to the diagnosis and management of EB from the point of view of the health-care provider/disease expert, there is a need for more research to define the key aspects of life with EB (i.e. diagnostic journey, treatment, management, daily living challenges, and overall disease burden) from the perspective of the patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of EB including subtype

• Resident of the US

• Informed Consent

• Patient must be 18 years or older

• If the survey is done by a caregiver, they must be a parent or legal guardian and must be 18 years or older to answer on behalf of a patient under 18 years or on behalf of a patient 18 years or older who is unable to answer for themselves.

• Must participate in and complete a one hour telephone interview

Exclusion Criteria:

• Patient failing to meet the inclusion criteria above

Related Conditions & MeSH terms

• Epidermolysis Bullosa

Intervention

Other:
• Survey
Survey Study

Locations

Country	Name	City	State
United States	Amicus Therapeutics	Cranbury	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Amicus Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Current quality of life burdens for EB patients		Outcome will be assessed immediately after subjects answer the questionnaire as this is a cross-sectional survey